Innate Pharma is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. These novel drugs consist of monoclonal antibodies that can activate the innate immune system.

Backed by Gilde as an investor, Innate Pharma has advanced its product pipeline to the clinical development stage and built strong commercial partnerships with Novo Nordisk and Bristol-Myers Squibb.

Innate Pharma operates from Marseille, France, and was successfully listed at Euronext Paris (IPH) after its IPO in 2006.